Editor's Choice
CARDIOVASCULAR PREVENTION / GUIDELINES/RECOMMENDATIONS
 
KEYWORDS
TOPICS
ABSTRACT
Cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD), is the most common cause of death worldwide. Despite decades of research into lifestyle factors and medications, we still cannot effectively prevent the occurrence of ASCVD or the many incident CVD events and their complications. Yet, in most countries, only a small percentage of the healthcare budget is allocated to (primary) prevention, and only a few nations have introduced effective integrated (coordinated) programmes in primary prevention to promote health education, invest in health as early as possible, and prevent adverse CVD events. The International Lipid Expert Panel SiMple tIps for the heaLthy hEart (ILEP-SMILE) responds to this significant ineffectiveness by offering the most comprehensive population approach, including early, effective education, improvement of all recognised risk factors, alongside those that remain frequently unmeasured, such as lipoprotein(a), factors which are often overlooked such as sleep disturbances and alcohol consumption, and the challenging aspect of stress, and its effect on cardiovascular health. Finally, ILEP-SMILE places considerable emphasis on adherence as a result of education; without it, even efficient lifestyle changes and the most innovative drugs may not yield the expected outcomes. This is also a loud call to action and international collaboration to jointly address the lifetime burden of cardiovascular disease.
REFERENCES (47)
1.
Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol 2020; 76: 2982-3021.
 
2.
Banach M, Toth PP, Bielecka-Dąbrowa A, Lewek J. Primary and secondary cardiovascular prevention: recent advances. Kardiol Pol 2024; 82: 1200-10.
 
3.
Hasbani NR, Ligthart S, Brown MR, et al. American Heart Association’s Life’s Simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease. Circulation 2022; 145: 808-18.
 
4.
Lloyd-Jones DM, Allen NB, Anderson CAM, et al.; American Heart Association. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation 2022; 146: e18-43.
 
5.
Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380: 219-29.
 
6.
Katsiki N, Mikhailidis DP, Bajraktari G, et al.; International Lipid Expert Panel (ILEP). Statin therapy in athletes and patients performing regular intense exercise – position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res 2020; 155: 104719.
 
7.
Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. Eur J Prev Cardiol 2023; 30: 1975-85.
 
8.
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis. Lancet 2020; 396: 1223-49.
 
9.
Mazidi M, Mikhailidis DP, Sattar N, et al.; International Lipid Expert Panel (ILEP) & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Association of types of dietary fats and all-cause and cause-specific mortality: a prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. Clin Nutr 2020; 39: 3677-86.
 
10.
Mazidi M, Katsiki N, Mikhailidis DP, Sattar N, Banach M. Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. Eur Heart J 2019; 40: 2870-9.
 
11.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2022: a pooled analysis. Lancet 2024; 404: 2077-93.
 
12.
Banach M, Surma S, Dzida G, et al. The prevention opportunities of retinopathy in diabetic patients – position paper endorsed by the Polish Lipid Association. Arch Med Sci 2024; 20: 1754-69.
 
13.
GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 2025; 405: 813-38.
 
14.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024; 403: 1027-50.
 
15.
Sebastian SA, Shah Y, Paul H, Arsene C. Life’s Essential 8 and the risk of cardiovascular disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2025; 32: 358-73.
 
16.
Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J 2011; 32: 1484-92.
 
17.
Wang S, Li Z, Wang X, et al. Associations between sleep duration and cardiovascular diseases: a meta-review and meta-analysis of observational and Mendelian randomization studies. Front Cardiovasc Med 2022; 9: 930000.
 
18.
Mazidi M, Shekoohi N, Katsiki N, Banach M. Longer sleep duration may negatively affect renal function. Int Urol Nephrol 2021; 53: 325-32.
 
19.
Ballesio A, Aquino MRJV, Kyle SD, Ferlazzo F, Lombardo C. The efficacy of digital cognitive behavioral therapy for insomnia (dCBT-I) in the real world: a meta-analysis. Sleep Med Rev 2022; 61: 101568.
 
20.
Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries. Lancet 2004; 364: 937-52.
 
21.
Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review. Psychol Bull 2009; 135: 627-53.
 
22.
Kutal S, Tulkki LJ, Sarkanen T, et al. Association between self-perceived stress and cryptogenic ischemic stroke in young adults: a case-control study. Neurology 2025; 104: e213369.
 
23.
Health at a Glance: Europe 2024. State of Health in the Eu Cycle: https://www.oecd.org/en/public....
 
24.
Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data. Lancet 2018; 391: 1513-23.
 
25.
GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018; 392: 1015-35.
 
26.
Khan SS, Coresh J, Pencina MJ, et al.; American Heart Association. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation 2023; 148: 1982-2004.
 
27.
Banach M, Surma S, Guzik TJ, et al. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention. Cardiovasc Res 2025; 121: 851-9.
 
28.
Sosnowska B, Toth PP, Razavi AC, Remaley AT, Blumenthal RS, Banach M. 2024: the year in cardiovascular disease – the year of lipoprotein(a) – research advances and new findings. Arch Med Sci 2025; 21: 355-73.
 
29.
Fogacci F, Di Micoli V, Sabouret P, Giovannini M, Cicero AFG. Lifestyle and lipoprotein(a) levels: does a specific counseling make sense? J Clin Med 2024; 13: 751.
 
30.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
 
31.
Bielecka-Dabrowa A, Lewek J, Sakowicz A, et al.; Cardioplus Investigators. Effects of implementing personalized health education in ambulatory care on cardiovascular risk factors, compliance and satisfaction with treatment. J Pers Med 2022; 12: 1583.
 
32.
Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur Heart J Open 2022; 2: oeac071.
 
33.
Banach M, Reiner Ž, Surma S, et al.; International Lipid Expert Panel (ILEP). 2024 Recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP). Drugs 2024; 84: 1541-77.
 
34.
Fernandez-Jimenez R, Jaslow R, Bansilal S, et al. Child health promotion in underserved communities: the FAMILIA trial. J Am Coll Cardiol 2019; 73: 2011-21.
 
35.
Fernandez-Jimenez R, Santos-Beneit G, de Cos-Gandoy A, et al. Prevalence and correlates of cardiovascular health among early adolescents enrolled in the SI! Program in Spain: a cross-sectional analysis. Eur J Prev Cardiol 2022; 29: e7-10.
 
36.
Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34: 2940-8.
 
37.
Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol 2016; 225: 184-96.
 
38.
Penson PE, Bruckert E, Marais D, et al.; International Lipid Expert Panel (ILEP). Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle 2022; 13: 1596-622.
 
39.
Sørensen K, Pelikan JM, Röthlin F, et al. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). BMC Public Health 2021; 21: 1-13.
 
40.
Zhang H, Plutzky J, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. J Am Coll Cardiol 2021; 77: 1736-47.
 
41.
Wang JB, Cadmus-Bertram LA, Natarajan L, et al. Wearable sensor/device (Fitbit One) and SMS prompts to increase physical activity. JAMA Intern Med 2016; 176: 385-92.
 
42.
Yeung AWK, Torkamani A, Butte AJ, et al. The promise of digital healthcare technologies. Front Public Health 2023; 11: 1196596.
 
43.
Miszalski-Jamka M, Malawski F, Goslinski J, et al. AI-based algorithm for assessing coronary artery calcium score on contrast-enhanced cardiac computed tomography scans. Eur Heart J 2024; 45 (Suppl. 1): ehae666.197.
 
44.
Fogacci F, Ray KK, Nicholls SJ, Cicero AFG. Reducing the global prevalence of cardiometabolic risk factors: a bet worth winning. Metabolism 2025; 163: 156084.
 
45.
Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016; 1: CD001800.
 
46.
Surma S, Sahebkar A, Banach M; endorsed by the International Lipid Expert Panel (ILEP). Low carbohydrate/ketogenic diet in the optimization of lipoprotein(a) levels: do we have sufficient evidence for any recommendation? Eur Heart J 2023; 44: 4904-6.
 
47.
Zhubi-Bakija F, Bajraktari G, Bytyçi I, et al.; International Lipid Expert Panel (ILEP). The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: a position paper from the International Lipid Expert Panel (ILEP). Clin Nutr 2021; 40: 255-76.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top